Veracyte (VCYT) Equity Average (2013 - 2026)

Veracyte has disclosed Equity Average across 14 years of filings, most recently posting $1.3 billion for Q1 2026.

• Equity Average for Q1 2026 came in at $1.3 billion, up 11.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 billion (up 11.94% YoY), and the FY2025 annual result was $1.2 billion, up 11.96% from the prior year.
• Equity Average came in at $1.3 billion for Q1 2026 at Veracyte, up from $1.3 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.3 billion in Q1 2026 to a low of $1.0 billion in Q4 2023.
• The 5-year median for Equity Average is $1.1 billion (2022), against an average of $1.1 billion.
• Peak annual rise in Equity Average reached 56.34% in 2022, while the deepest fall reached 3.64% in 2022.
• Veracyte's Equity Average stood at $1.1 billion in 2022, then dropped by 1.19% to $1.0 billion in 2023, then climbed by 12.1% to $1.2 billion in 2024, then rose by 9.15% to $1.3 billion in 2025, then gained by 3.38% to $1.3 billion in 2026.
• The last three Equity Average figures came in at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.